PMID- 33062710 OWN - NLM STAT- MEDLINE DCOM- 20210823 LR - 20220417 IS - 2314-6753 (Electronic) IS - 2314-6745 (Print) VI - 2020 DP - 2020 TI - Poor Control of Plasma Triglycerides Is Associated with Early Decline of Estimated Glomerular Filtration Rates in New-Onset Type 2 Diabetes in China: Results from a 3-Year Follow-Up Study. PG - 3613041 LID - 10.1155/2020/3613041 [doi] LID - 3613041 AB - OBJECTIVE: Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease (ESRD). Even after strict control of obesity, hyperglycemia, and hypertension, some patients still progress rapidly. Previous studies suggested diabetic dyslipidemia might be one of the factors responsible for this high residual risk. This study aims to explore the impact of long-term lipid control on renal outcome in new-onset type 2 diabetes mellitus (T2DM). METHODS: We conducted a 3-year follow-up study, involving 283 subjects with new-onset T2DM, and observed the effect of baseline and follow-up metabolic abnormalities, especially dyslipidemia, on the early damage of kidney function using multiple logistic regression analysis. RESULTS: After 3 years follow-up, patients achieved a better control of body weight, hypertension, and blood glucose. The most reduced eGFR group shared the least reduced BMI and LDL-C, as well as the greatest increase in TG levels. Only TG in the follow-up, not any of the baseline data, nor obesity, blood glucose, BP, or LDL-C in the follow-up, was found to be significantly correlated with the most reduced eGFR. Compared with patients with constantly abnormal TG levels, the risks were even higher in the subjects who experienced a transition from normal TG to hypertriglyceridemia (OR = 2.576 versus OR = 2.184, after multiple adjustment), and by tight controlling of TG, patients started with abnormal baseline TG levels could reduce the risk of DKD progression to the same low levels as the TG-constantly-normal group. CONCLUSION: This study emphasized the importance of long-term TG control in East Asian patients with new-onset T2DM: TG control can delay the decline of kidney function in the early stage of DKD, and reversal of hypertriglyceridemia may undo the risks of the past. It is time to pay more attention to the control of TG in new-onset T2DM. CI - Copyright (c) 2020 Chuan Wang et al. FAU - Wang, Chuan AU - Wang C AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. FAU - Wang, Lingshu AU - Wang L AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. FAU - Liang, Kai AU - Liang K AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. FAU - Yan, Fei AU - Yan F AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. FAU - Hou, Xinguo AU - Hou X AUID- ORCID: 0000-0003-2045-1290 AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. FAU - Liu, Fuqiang AU - Liu F AUID- ORCID: 0000-0002-9950-3673 AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. FAU - Chen, Li AU - Chen L AUID- ORCID: 0000-0001-7670-8062 AD - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. AD - Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, 250012, China. AD - Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. AD - Jinan Clinical Research Center for Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, Shandong, 250012, China. LA - eng PT - Journal Article DEP - 20200928 PL - England TA - J Diabetes Res JT - Journal of diabetes research JID - 101605237 RN - 0 (Blood Glucose) RN - 0 (Lipids) RN - 0 (Triglycerides) SB - IM MH - Aged MH - Blood Glucose MH - Blood Pressure MH - Body Weight MH - China/epidemiology MH - Diabetes Mellitus, Type 2/*blood/*complications MH - Diabetic Nephropathies/*blood/complications MH - Dyslipidemias/blood MH - Female MH - Follow-Up Studies MH - *Glomerular Filtration Rate MH - Humans MH - Hyperglycemia/complications MH - Hypertension/complications MH - Kidney Failure, Chronic/blood/complications MH - Lipids/blood/chemistry MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Obesity/complications MH - Regression Analysis MH - Risk Factors MH - Triglycerides/*blood PMC - PMC7542506 COIS- The authors declare that there is no conflict of interest regarding the publication of this paper. EDAT- 2020/10/17 06:00 MHDA- 2021/08/24 06:00 PMCR- 2020/09/28 CRDT- 2020/10/16 05:56 PHST- 2020/05/18 00:00 [received] PHST- 2020/07/19 00:00 [revised] PHST- 2020/08/04 00:00 [accepted] PHST- 2020/10/16 05:56 [entrez] PHST- 2020/10/17 06:00 [pubmed] PHST- 2021/08/24 06:00 [medline] PHST- 2020/09/28 00:00 [pmc-release] AID - 10.1155/2020/3613041 [doi] PST - epublish SO - J Diabetes Res. 2020 Sep 28;2020:3613041. doi: 10.1155/2020/3613041. eCollection 2020.